Medtronic Leads $100M Investment in Pulnovo Medical; Feimou Medical Secures Nearly RMB 100 Million in Series A Funding

1. Rehabilitation Robots Complete Batch "Practical Training"

Recently, at Yangzhi Rehabilitation Hospital affiliated with Tongji University, a public tertiary rehabilitation hospital in Shanghai, rehabilitation robots have been deployed on a large scale, covering the entire rehabilitation network cycle and becoming a "standard feature" for assisting therapists. These robots can provide highly repetitive and precise training and simulate dozens of real-life and occupational scenarios. Currently, over 80% of the rehabilitation robots in the hospital are domestically produced in China. The integration of medical and engineering advancements is accelerating, with breakthroughs such as markerless visual capture contributing to cost reduction and efficiency improvement for home-use products. As policies clarify pricing for "AI-assisted" rehabilitation and include exoskeleton robots in the catalog of assistive devices, industry experts predict that rehabilitation robots moving beyond hospitals to become "24/7 online" rehabilitation assistants for the elderly is now within sight. (Sina News)

2. Beijing Boston AI Digital Fitting System "Palm" Smart Fitting

Recently, Beijing Boston Optics Technology Co., Ltd. launched the AI Digital Fitting System, with the core concept of "mastering intelligent fitting at your fingertips." The system deeply integrates AI technology with digital fitting processes. It overcomes the limitations of traditional fitting models by utilizing intelligent algorithms and digital methods to achieve precision, efficiency, and convenience in the fitting process, making accurate fitting easily accessible. Without complex operations, users can obtain highly personalized fitting solutions within a short period, significantly improving the fitting experience and outcomes. The introduction of Beijing Boston’s AI Digital Fitting System marks an important step toward intelligence and digitization in the fitting industry, setting a new technical benchmark and service model for the sector. It is expected to drive technological innovation and service upgrades across the entire fitting field, meeting the market's urgent demand for high-quality, precise fitting services. (Eye Future)

3. Hong Kong Develops AI Pathology System for Precise Diagnosis of Multiple Cancers

Recently, a research team led by the Hong Kong University of Science and Technology (HKUST) developed a groundbreaking artificial intelligence (AI) pathology analysis system named PRET (Pan-cancer Recognition with Efficient Training), which can accurately identify various types of cancer with only a small number of samples and without additional training. This breakthrough significantly enhances the flexibility and efficiency of AI-assisted healthcare, marking an important step towards the widespread application of intelligent pathology. The system introduces the concept of "contextual learning" from natural language processing into pathology image analysis, enabling the model to instantly adapt to new cancer types during the inference phase by referencing just one to eight labeled tumor slices, and to perform diagnostic tasks such as cancer screening, tumor subtype classification, and tumor segmentation. (BioSpectrum Asia)

4. Medtronic Leads Investment in This Chinese Innovative Medical Device Company

Recently, Pulnovo Medical announced the completion of a $100 million oversubscribed financing round, led by Medtronic, with continued participation from existing investors such as EQT and Qiming Venture Partners, as well as involvement from global institutions like Sequoia China. Pulnovo Medical’s self-developed Pulmonary Artery Denervation (PADN) system has been approved in seven countries, received FDA Breakthrough Device Designation, initiated two clinical trials, and has been included in multiple international guidelines. This financing round is one of the major events in the medical device sector this year, with Medtronic's lead investment highlighting the market potential in the field of pulmonary hypertension interventional treatment. The proceeds will be used for ongoing clinical research, global regulatory submissions, international commercialization efforts, and investment in core technology platforms, providing financial support for the company’s globalization strategy. (Medical Device News)

5. Successful Clinical Implantation of China-Made ProStyle M Mitral Valve System

Recently, the ProStyle M Mitral Valve System, independently developed by Goldschmidt Bio, completed the confirmatory clinical research implantation, marking a crucial step forward in China's transcatheter mitral valve treatment field. The surgery was led by experts Wang Chunsheng and Wei Lai from Zhongshan Hospital, Fudan University, with full ultrasound guidance, eliminating the need for radiation, ensuring patient safety, and reducing radiation exposure to medical staff. Previously, ProStyle M had undergone human trials, showing excellent valve anchoring effects in 10 elderly patients without any regurgitation. Mitral regurgitation is common, and traditional surgeries carry high risks. ProStyle M, with its eccentric structure, Micro-Ex™ anti-calcification technology, and AirBo™ dry storage technology, reduces surgical difficulty and risk while enhancing valve stability and durability, precisely addressing key challenges in clinical treatment. (I Love Valves)

6. Oriental Interstellar Stem Cell Angel Fund Launches with a Scale of 2 Billion Yuan

Recently, at the 2026 Zhangjiang Medipost International Innovation Conference · Advanced Therapy Forum and the 2026 Shanghai Stem Cell Conference, the Oriental Starship Stem Cell Angel Fund was officially launched, with a fund size of 2 billion yuan. The fund is led by Shanghai Tongjin Stem Cell Technology Co., Ltd., and jointly initiated by Shenzhen Qianhai Zhongli Equity Investment Fund Management Co., Ltd., Shanghai Nanqin Investment Management Co., Ltd., and Zhejiang Tianma Industrial Co., Ltd. It will focus on investing in cutting-edge stem cell technologies, anti-aging intervention mechanisms, and related upstream and downstream high-barrier projects, aiming to build a comprehensive industrial investment ecosystem and promote development and innovation in the stem cell field. (East Money Finance)

7. What is the medical device public service platform?

The Medical Device Public Service Platform is a key project co-developed by the Orthomed Group in collaboration with local governments, industrial parks, medical institutions, and research universities. It focuses on incubating, transforming, and investing in cutting-edge and innovative global medical device technologies. By establishing scientific research and technology transfer mechanisms aligned with international standards, it operates through an open and shared model to attract top-tier scientific researchers, doctors, and innovators from around the world. The platform provides comprehensive industry technical services covering R&D transformation, incubation, and investment, fostering significant innovations and applications in medical devices. This initiative strongly supports the development of the medical device industry and technological innovation. (Compiled by Orthomed)

8. Feimiao Medical Completes Nearly 100 Million Yuan in Angel Round Financing

Recently, Shenzhen Feimou Medical Device Technology Co., Ltd. announced the completion of an angel round of financing worth nearly 100 million yuan. This round of financing was led by YuanSheng Venture Capital, with participation from Zero2IPO Group, Zero2IPO University Student Entrepreneurship Fund, and Yingtong Lianchuang. The funds will be used for product technology iteration and upgrades, clinical trials, animal experiments, etc. Feimou Medical was founded in November 2022 by Dr. Zhang Yao in collaboration with the CAS Medical Femtosecond Laser Team and senior experts in medical industry industrialization. The core team consists of veterans in the ophthalmic device field, with extensive experience both domestically and internationally. As one of the few companies in China's ophthalmic femtosecond laser sector that truly possesses forward R&D capabilities, technology and product orientation are at the core of the company’s philosophy. Rather than aiming solely to "produce a domestically-made full-femtosecond device," the company focuses on solid underlying platform capabilities to develop the next generation of personalized full-femtosecond technology. Product R&D is centered on differentiation, with rapid iterations leading to a richer product portfolio. (VcBeat)